Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mouthwashes to Decrease SARS-CoV-2 Salivary Viral Load
NCT05543603Completed
- Start
- Apr 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of chlorhexidine, o-Cymen-5-ol and Zinc chloride in coronavirus disease 2019 (COVID-19) (4 arms). Primary endpoints: Change of SARS-Cov2 viral load in saliva at 60 months and Change of infective SARS-Cov2 viral load in saliva at 60 months. Started Apr 2021; status: completed.
02
Drugs
chlorhexidineo-Cymen-5-olZinc chloride
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05543603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543603.